Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of Ruxolitinib and
Chidamide intensified conditioning regimen in patients with Acute T cell Lymphoblast
leukemia/ lymphoblastic lymphoma Underwenting Haploidenticl Peripheral blood Stem Cell
Transplantation.